Blueprint Medicines Corp (NAS:BPMC)
$ 102.71 -0.92 (-0.89%) Market Cap: 6.43 Bil Enterprise Value: 6.17 Bil PE Ratio: 0 PB Ratio: 20.71 GF Score: 74/100

Blueprint Medicines Corp at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 12:35PM GMT
Release Date Price: $72.9 (-0.37%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. And before we get going here, I have to give the requisite disclosures. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk. I am David Lebowitz, one of the biotechnology analysts here, and I would like to welcome to the stage from Blueprint Medicines, CEO Jeff Albers. If you could just first, I guess, introduce yourself, talk about the company and its overall mission, that would be great.

Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

Sure. So first off, on behalf of all the employees of Blueprint Medicines, I want to thank you, David, and Morgan Stanley team for including us in the conference. And would refer you to our securities filings our website as we'll be, I suspect, making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot